SK Hynix Targets $29.4 Billion Nasdaq Listing to Expand AI Chip Business 
Samsung, SK Hynix to Unveil Record AI and Semiconductor Investment Plans Worth Over $646 Billion 
OpenAI IPO Delay Weighs on SoftBank Shares as AI Valuation Concerns Grow 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
China Eastern Orders 25 Airbus A330neo Jets in $9.35 Billion Deal to Boost International Expansion 
Samsung and SK Hynix Shares Jump After Micron Earnings Boost AI Chip Optimism 
Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Apple Supplier Stocks Slide as Samsung, SK Hynix Lead Selloff After Apple Price Hikes 
Bayer Wins Major U.S. Supreme Court Roundup Lawsuit, Shares Surge 
Doncasters Raises $919 Million in NYSE IPO as Aerospace Growth Accelerates 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
Trip.com Shares Tumble After Q1 Profit Drops and Weak Revenue Growth Outlook 
Nomura Stock Upgraded to Buy by BofA as Stronger ROE and Earnings Growth Boost Outlook 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
CAMBRIDGE, Mass., Feb. 28, 2017 -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will present at the Cowen and Company 37th Annual Health Care Conference. The presentation is scheduled for Tuesday, March 7th at 10:40 a.m. ET.
The webcast of the presentation will be available live on the “Investors” section of the company’s website located at www.momentapharma.com. A replay of the presentation will be posted on the Momenta website approximately one hour after the event.
About Momenta
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for autoimmune indications.
To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release.
Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.
Contact: Sarah Carmody Momenta Pharmaceuticals 1-617-395-5189 [email protected]
